[Fraxiparin as a component of lymphotropic polychemotherapy of locally spread valvular cancer in patients with chronic venous insufficiency].
A total of 29 female patients with locally spread cancer of the vulva in chronic venous insufficiency underwent lymphotropic polychemotherapy. Of these, 16 subjects (55.2%) had varicosis, 13 (44.8%) presented with chronic thrombophlebitis. All above patients were found to run a high risk for development of thromboembolic complications. Administration of the thrombolytic-complication prophylaxis is exercised through the use of fraxiparin, a drug of choice. With lymphotropic polychemotherapy instituted in patients with locally spread carcinoma of the vulva and chronic venous insufficiency, fraxiparin ("Sanofi-Synthelabo") proved to be a highly effective means of prophylaxis against thromboembolic complications.
Tkachuk
T Ie
TIe
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D017762:Nadroparin / Q000008:administration & dosage / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000150:complications / Q000188:drug therapy*; D014648:Varicose Veins / Q000150:complications / Q000188:drug therapy*; D014846:Vulvar Neoplasms / Q000150:complications* / Q000188:drug therapy
D005343:Fibrinolytic Agents; D017762:Nadroparin; D006493:Heparin